| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Extraocular Extension Melanoma | |||||
| Recurrent Intraocular Melanoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Eye Neoplasms | |||||
| Melanoma | |||||
| 3 | More general conditions related to this trial | ||||
| Eye Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Germ Cell and Embryonal | |||||
| Neoplasms, Nerve Tissue | |||||
| Neuroectodermal Tumors | |||||
| Neuroendocrine Tumors | |||||
| Nevi and Melanomas | |||||
| 4 | Interventions listed in this trial | ||||
| gp100 antigen | |||||
| interleukin-2 | |||||
| MART-1 antigen | |||||
| Montanide ISA-51 | |||||
| 5 | More general drug interventions related to this trial | ||||
| Analgesics | |||||
| Analgesics, Non-Narcotic | |||||
| Antineoplastic Agents | |||||
| Central Nervous System Agents | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Sensory System Agents | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Cancer Institute (NCI) | |||||
|
